Molecular mechanisms involved in the beneficial effect of BET inhibition in experimental renal disease

June 5, 2017 - ERA-EDTA, Madrid Spain - Marta Ruiz-Ortega – Fundación Jiménez Díaz, Madrid, Spain

During a satellite symposium at the ERA-EDTA in Madrid, Spain, organised by PACE-CME, Marta Ruiz-Ortega sheds light on the new and exciting field of epigenetics, and how BET inhibition might provide an interesting therapeutic target in renal disease. She shares experimental data dat demonstrate the beneficial effects of BET inhibition.

Epigenetic mechanisms can determine health and disease, and can thus serve as therapeutic targets - an introduction to BET proteins 0:20
Mechanistic insights into the effects of BET inhibition from experimental studies 5:25
Studies in rnal disease show that BET inhibition reduces inflammation via two pathways 12:57
BET inhibition also reduces fibrosis, which is commonly seen in renal disease 15:45
Summary of downstream effects of BET inhibition and implications for its potential as a therapy in humans 17:31

Educational information

To summarise the epidemiology and pathophysiology of patients at high cardiovascular risk with diabetes
To understand the origin of the high residual cardiovascular risk in patients with diabetes and kidney disease
To review how BET inhibition affects gene expression via epigenetic mechanisms, as a novel strategy to improve outcomes in CVD and CKD
To update and review current clinical research programmes evaluating the role of epigenetic regulation of gene expression in CVD management

Faculty & Disclosures

Marta Ruiz-Ortega, PhD, Fundación Jiménez Díaz,Madrid, Spain

CME Accreditation

This lecture was part of a CME accredited symposium: Managing CKD, Diabetes & CVD: Is epigenetics a new way forward? held at ERA-EDTA in Madrid, Spain.

Funding

The symposium was supported by an unrestricted educational grant from Resverlogix Corp